Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05367700 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

StatusUnknown
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 13, 2023 (before its estimated December 30, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Recruiting
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 30, 2022 to Dec 30, 2024 · Completion date: Sep 30, 2024 to Sep 30, 2026 · Start date changed from estimate of Apr 30, 2022 to Apr 28, 2022 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Dec 30, 2022 to Dec 30, 2024
    • Completion date: Sep 30, 2024 to Sep 30, 2026
    • Start date changed from estimate of Apr 30, 2022 to Apr 28, 2022
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.
Trial Details
NCT Number NCT05367700
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions CML, Chronic Phase, CML, Accelerated Phase
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov